The US FDA has a lot of work to do to encourage both biosimilar competition and innovation in biological product development, if stakeholder comments at a recent public hearing are any indication.
The agency can help spur biosimilar development and market success by finalizing guidance on interchangeability, enhancing public education efforts about...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?